By scrutinizing tumor samples from patients with metastatic melanoma before and during treatment with pembrolizumab, they found that patients who responded to PD-1 inhibitor treatment had a large extent of CD8+ T cells infiltration at stroma-tumor margins, while drug-resistant patients displayed significantly low CD8+ T cells infiltration [101]. Here, CD8A is linked to metastatic melanoma.